Table 2.
Diagnosis | Patients n | Pre-SARS-COV-2 | Patients n | During-SARS-COV-2 | ||
---|---|---|---|---|---|---|
Antibiotics/Analgesics n(%) | local treatment n(%) | Antibiotics/Analgesics n (%) | Local treatment n (%) | |||
Group1 | 413 | 45 (10.9%) | 364 (88.1%) | 858 | 219 (25.5%) | 583 (67.9%) |
Group2 | 314 | 61 (19.4%) | 259 (82.5%) | 529 | 227 (44.9%) | 367 (69.4%) |
Group3 | 24 | 1 (4.2%) | 7 (29.2%) | 56 | 2 (3.6%) | 10 (17.9%) |
Group4 | 161 | 76 (47.2%) | 132 (82.0%) | 227 | 99 (43.6%) | 156 (68.7%) |
Group5 | 695 | 103 (14.8%) | 655 (94.2%) | 492 | 208 (42.3%) | 474 (96.3%) |
Group6 | 58 | 6 (6.1%) | 31 (53.4%) | 23 | 6 (26.1%) | 7 (30.4%) |
Group7 | 51 | 12 (23.5%) | 37 (72.5%) | 257 | 197 (76.7%) | 39 (15.2%) |
Group1: Acute Pulpitis (K04.0) and/or Acute apical periodontitis (K04.4)
Group2: Acute gingivitis (K05.0) and/or Acute pericoronitis (K05.2)
Group3: Temporomandibular joint disorders (K07.6)
Group4: Cellulitis and abscess of mouth (K12.2)
Group5: Open wound of lip and/or oral cavity (S01.5)
Group6: Fracture of tooth (S02.5)
Group7: Others (non-emergency diseases, including diagnoses related to prosthesis, aesthetic, recall or maintenance)